

**ANNEXURE I**

**Format to be submitted by listed entity on quarterly basis**

- |                            |                                  |
|----------------------------|----------------------------------|
| 1. Name of Listed Entity   | - Dishman Carbogen Amcis Limited |
| 2. Quarter ending          | - 31-Dec-2018                    |
| 3. Script code Code/Symbol | - BSE: 540701; NSE: DCAL         |

<b>i. Composition of Board of Director</b>											
Title (Mr./Ms)	Name of the Director	DIN	PAN	Category (Chairperson /Executive/ Non-Executive/ Independent/ Nominee)	Sub Category	Date of Appointment	Date of Cessation	Tenure	No of Directorship in listed entities including this listed entity	No of memberships in Audit/ Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity
Mr.	Janmejy R. Vyas	00004730	AAGPV5002P	C,ED	MD	01-Mar-2015			1	1	0
Mrs.	Deohooti J. Vyas	00004876	AAJPV5327Q	ED		03-Sep-2016			1	0	0
Mr.	Arpit J. Vyas	01540057	ADSPV7509A	ED	MD	01-Jun-2014			1	0	0
Mr.	Rajendra S. Shah	00061922	AEOPS0341G	ID		02-Apr-2015		60	3	1	2
Mr.	Sanjay S. Majmudar	00091305	AAPPM5037Q	ID		01-Apr-2014		60	5	4	3
Mr.	Ashok C. Gandhi	00022507	ABCPG5178J	ID		01-Apr-2014		60	5	7	1
Mr.	Subir Kumar Das	02237356	AALPD4981C	ID		15-Dec-2014		60	2	2	1
Mr.	Mark C. Griffiths	06981744	AVEPG0006D	NED		01-Sep-2014			1	0	0

Company Remarks	Note: As required by Regulation 26(1) of SEBI (LODR) Regulations, 2015, the disclosure includes Membership and Chairmanship of Audit Committees and Stakeholders Relationship Committees in all public limited Companies (listed or unlisted)
Whether Permanent chairperson appointed	Yes

**ii. Composition of Committees**

<b>a. Audit Committee</b>						
Sr. No.	Name of the Director	Category	Chairperson/Membership	Appointment Date	Cessation Date	
1	Subir Kumar Das	ID	Member	17-Mar-2017		
2	Ashok C. Gandhi	ID	Member	17-Mar-2017		
3	Sanjay S. Majmudar	ID	Chairperson	17-Mar-2017		

Company Remarks	Note: 1. Mr. Subir Kumar Das has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders & Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the Board of the Company, hence, Mr. Subir Kumar Das has been appointed with his existing terms and
-----------------	--

	<p>conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 15th December, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p> <p>2. Mr. Sanjay S. Majmudar has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders &amp; Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Sanjay S. Majmudar has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st April, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p> <p>3. Mr. Ashok C. Gandhi has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders &amp; Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Ashok C. Gandhi has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st April, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p>
Whether Permanent chairperson appointed	Yes

**b. Stakeholders Relationship Committee**

Sr. No.	Name of the Director	Category	Chairperson/Membership	Appointment Date	Cessation Date
1	Janmejy R. Vyas	C,ED	Member	17-Mar-2017	
2	Ashok C. Gandhi	ID	Member	17-Mar-2017	
3	Sanjay S. Majmudar	ID	Chairperson	17-Mar-2017	

Company Remarks	<p>Note:</p> <p>1. Mr. Sanjay S. Majmudar has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders &amp; Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Sanjay S. Majmudar has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st April, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p> <p>2. Mr. Ashok C. Gandhi has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders &amp; Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Ashok C. Gandhi has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st April, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p>
-----------------	--

	3. Mr. Janmejy R. Vyas has been appointed as a Chairman & Managing Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders & Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Janmejy R. Vyas has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st March, 2015 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.
Whether Permanent chairperson appointed	Yes

c. Risk Management Committee					
Sr. No.	Name of the Director	Category	Chairperson/Membership	Appointment Date	Cessation Date

Company Remarks	
Whether Permanent chairperson appointed	

d. Nomination and Remuneration Committee					
Sr. No.	Name of the Director	Category	Chairperson/Membership	Appointment Date	Cessation Date
1	Subir Kumar Das	ID	Member	17-Mar-2017	
2	Ashok C. Gandhi	ID	Member	17-Mar-2017	
3	Sanjay S. Majmudar	ID	Chairperson	17-Mar-2017	

Company Remarks	<p>Note:</p> <p>1. Mr. Subir Kumar Das has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders &amp; Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the Board of the Company, hence, Mr. Subir Kumar Das has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 15th December, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p> <p>2. Mr. Sanjay S. Majmudar has been appointed as an Independent Director pursuant to the Scheme of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders &amp; Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Sanjay S. Majmudar has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st April, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.</p> <p>3. Mr. Ashok C. Gandhi has been appointed as an Independent Director pursuant to the Scheme</p>
-----------------	---

	of Arrangement and Amalgamation amongst the Company; Dishman Pharmaceuticals and Chemicals Ltd. (DPCL); Dishman Care Limited and their respective Shareholders & Creditors (Scheme) sanctioned by Honble High Court of Gujarat vide order dated 16th December, 2016. As per the said Scheme, Directors of DPCL shall require to be appointed on the board of the Company, hence, Mr. Ashok C. Gandhi has been appointed with his existing terms and conditions as approved by the Board of Directors and Shareholders of Amalgamating Company viz. DPCL i.e. w.e.f. 1st April, 2014 upon coming into effect of the said Scheme on 17th March, 2017 as well as in Committee(s) of the Board of Directors of the Company.
Whether Permanent chairperson appointed	Yes

<b>iii. Meeting of Board of Directors</b>	
<b>Date(s) of Meeting (if any) in the previous quarter</b>	<b>Date(s) of Meeting (if any) in the relevant quarter</b>
02-Jul-2018	01-Nov-2018
25-Jul-2018	28-Nov-2018

Company Remarks	
Maximum gap between any two consecutive (in number of days)	98

<b>iv. Meeting of Committees</b>				
Name of the Committee	Date(s) of meeting during of the committee in the previous quarter	Date(s) of meeting of the committee in the relevant quarter	Requirement of Quorum met (details)	Whether requirement of Quorum met (Yes/No)
Audit Committee	25-Jul-2018	01-Nov-2018	3	Yes
Audit Committee		28-Nov-2018	3	Yes
Stakeholders Relationship Committee	25-Jul-2018	01-Nov-2018	3	Yes
Nomination & Remuneration Committee		28-Nov-2018	3	Yes

Company Remarks	
Maximum gap between any two consecutive (in number of days) [Only for Audit Committee]	98

<b>v. Related Party Transactions</b>		
Subject	Compliance status (Yes/No/NA)	Remark
Whether prior approval of audit committee obtained	Yes	
Whether shareholder approval obtained for material RPT	Not Applicable	
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes	

Disclosure of notes on related party transactions and Disclosure of notes of material related party transactions	<b>No material transactions as per Regulation 23 of SEBI (LODR), 2015 have been transacted during the quarter ended 31st December, 2018.</b>
--	--

**VI. Affirmations**

1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - **Yes**
2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
  - a. Audit Committee - **Yes**
  - b. Nomination & remuneration committee - **Yes**
  - c. Stakeholders relationship committee - **Yes**
  - d. Risk management committee (applicable to the top 100 listed entities) - **Not applicable**
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. - **Yes**
4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.- **Yes**
  
5. a. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. - **Yes**  
b. Any comments/observations/advice of Board of Directors may be mentioned here:

**Name** : **SHRIMA DAVE**  
**Designation** : **Company Secretary & Compliance Officer**